Patel and Singh recently demonstrated that apigenin treatment (25–50 mg/kg) for 2 weeks attenuates LPS-induced parkinsonism in experimental rats targeting TLR/NF-κB and Nrf2/HO-1 signaling pathways. This evidence concerns the gene NFKB1 and Parkinson disease.